Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma

Trial Profile

Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Dec 2011 Results assessing the effects of treatment on health-related quality of life published in the European Journal of Cancer.
    • 07 Jun 2011 Quality of life results (after 2 years) presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Jan 2011 Results published in Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top